Explore MSD

Login
Register

Products
- Bridion®
- KEYTRUDA®
- RotaTeq®
- VARIVAX®
- ProQuad®
- M-M-R®II
- Pneumovax® 23
- Invanz®
- Cubicin®
- SIVEXTRO®
- Prevymis®
- ZERBAXA®
- LENVIMA®
- Tienam®
- KEYTRUDA® + LENVIMA®
- GARDASIL®9
- VAXNEUVANCE™
Therapeutic Areas
Resources
Events

Home Redefining Survival Expectations with Pembrolizumab as 2L Treatment Therapy for R/R cHL

Redefining Survival Expectations with Pembrolizumab as 2L Treatment Therapy for R/R cHL

May 2, 2022 Playtime: 19:25 Minutes

Chapter 2

Login or register to access this content.

What can we help you find?

Search for

Privacy Policy
Terms of Use
Accessibility

Merck Sharp & Dohme (Malaysia) Sdn. Bhd., B-22-1 & B-22-2, The Ascent Paradigm, 1, Jalan SS 7/26A, Kelana Jaya, Petaling Jaya 47301, Selangor, Malaysia. | Tel: +603 7499 1600 | Fax: +603 7499 1700 | www.msd-malaysia.com

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.